Minirin (Desmopressin Acetate)

Desmopressin acetate mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney’s collecting ducts. This triggers a cascade that raises cyclic AMP, causing aquaporin‑2 water channels to move to the cell surface, which increases water reabsorption and concentrates urine. It also promotes release of factor VIII and von Willebrand factor from endothelial cells, aiding haemostasis.

The exact dose of Minirin is individualized by the prescribing clinician based on the specific indication, patient age, weight, renal function, and response to therapy. Dosage adjustments may be needed for elderly patients, those with impaired kidney function, or when used alongside interacting medications. Patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety data for desmopressin acetate in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and alternatives with their healthcare provider before starting Minirin.

To request Minirin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Minirin (desmopressin) is a synthetic vasopressin analogue that offers a longer half‑life and greater selectivity for V2 receptors than natural vasopressin, resulting in fewer cardiovascular side effects. Unlike some diuretics that increase urine output, Minirin reduces urine volume. It is generally preferred for chronic management of diabetes insipidus and nocturnal enuresis due to its oral availability and predictable effect.

Minirin should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the product in its original packaging to protect it from moisture and light. Do not store in areas with high humidity or extreme heat, and keep it out of reach of children.

Minirin is supplied as an oral formulation. The tablet or oral liquid should be taken exactly as prescribed, usually with a glass of water. It can be taken with or without food, but patients should follow any specific instructions from their prescriber regarding timing relative to meals or other medications.

The most serious risks include severe hyponatremia, which can lead to cerebral edema, seizures, or coma, and water intoxication from excessive fluid retention. Patients should be alert for symptoms such as headache, nausea, confusion, weakness, or sudden weight gain, and seek medical attention promptly if these occur.

Minirin is contraindicated in individuals with known hypersensitivity to desmopressin acetate or any of its excipients. It should also be avoided in patients with uncontrolled hypertension, severe renal impairment, or those who are unable to monitor fluid balance and serum sodium levels adequately.